Header Logo

HESHAM MOHAMED

Address3701 KIRBY DRIVE
Houston, TX 77098
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Fadel MG, Rauf S, Mohamed HS, Yusuf S, Hayes AJ, Power K, Smith MJ. The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study. Ann Surg Oncol. 2023 Jul; 30(7):4333-4340. PMID: 37061649.
      Citations:    
    2. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, R?cher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan; 10(1):e46-e58. PMID: 36370742.
      Citations: 15     Fields:    
    3. Kylm? AK, Jouhi L, Listyarifah D, Mohamed H, M?kitie A, Remes SM, Haglund C, Atula T, Nieminen MT, Sorsa T, Hagstr?m J. Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma. Br J Cancer. 2018 07; 119(1):89-95. PMID: 29930251; PMCID: PMC6035174.
      Citations:    
    4. Kim DW, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese E, Saussele S. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018 Aug; 97(8):1357-1367. PMID: 29556695; PMCID: PMC6018625.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    5. Jouhi L, Atula T, Saarilahti K, Hagstr?m J, Haglund C, Mohamed H, M?kitie A, Keski-S?ntti H. Changing trends in the management of the neck in oropharyngeal squamous cell carcinoma. Head Neck. 2017 07; 39(7):1412-1420. PMID: 28464452.
      Citations:    
    6. Shah NP, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Saglio G, Rousselot P, Hochhaus A. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. PMID: 27192969; PMCID: PMC5094534.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    7. Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1. PMID: 27133948.
      Citations: 4     Fields:    Translation:Humans
    8. Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407. PMID: 26998677; PMCID: PMC5071708.
      Citations: 21     Fields:    Translation:HumansCells
    9. Shah NP, Cortes JE, Schiffer CA, le Coutre P, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G, Guilhot F, Br?mmendorf TH. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24. PMID: 24569263; PMCID: PMC4915794.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    10. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Chuah C, Pavlovsky C, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A, Boqu? C, Mayer J. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500. PMID: 24311723; PMCID: PMC4190618.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    MOHAMED's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (80)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _